NPM1-mutant AML encompasses a spectrum of biological heterogeneity driven by the co-occurrence of genetic mutations (e.g., FLT3 internal tandem duplications) emerging at the transcriptional level (Mer et al., 2021). The gene discussed is FLT3; the disease is acute myeloid leukemia.